Tethis is set to gain insights from analytical characterisation of liquid biopsy samples from MBC patients. Credit: Komsan Loonprom/Shutterstock.com.

Tethis has announced the enrolment of the first two patients in the TET-22-001 clinical study of its See.d platform.

Being conducted at the European Institute of Oncology in Milan, Italy, the study is designed to assess the performance of the Tethis See.d instrument and nanocoated SmartBioSurface (SBS) slides for preparing cytological samples and plasma from whole blood for liquid biopsy applications.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Titled ‘Feasibility evaluation of See.d pre-analytical platform performance: from whole blood to plasma and SmartBioSurface slides for liquid biopsy applications,’ the study aims to validate the use of the See.d instrument in a clinical setting.

Blood samples from 20 healthy volunteers, enhanced with reference DNA and tumour model cells, have already been processed, demonstrating the system’s capability to standardise and produce high-quality cytology slides and plasma samples.

The enrolment of the first two metastatic breast cancer patients marks a significant milestone in the study, which plans to include a total of 25 participants.

The samples from these patients were processed using the See.d instrument, yielding plasma and cytology slides for further analysis of cell-free DNA and circulating tumour cells.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This study will provide the first ‘real world’ data on the See.d instrument’s performance and ease of use in a hospital laboratory environment.

Subsequently, a performance study will be conducted to obtain CE-IVD marking for the See.d and SBS slides.

Tethis is also set to gain valuable insights from the initial analytical characterisation of liquid biopsy samples from the MBC patients.

The liquid biopsy results will be compared with concurrent tissue biopsies to support the development of a non-invasive liquid biopsy test.

Tethis CEO Dr Holger Neecke said: “The importance of standardising sample preparation cannot be overstated, as it significantly enhances the precision of downstream analytical tests.

“See.d-processed samples facilitate multiomic liquid biopsy analysis, allowing examination of white blood cells and rare circulating tumour cells, along with cell-free biomarkers, all from a single blood draw.

“This holistic view of the tumour status not only empowers clinicians to guide patients towards the most suitable therapeutic options but also provides translational researchers with a deeper understanding of tumour development, paving the way for the discovery of novel targeted therapies and biomarkers.”